PRINCETON, N.J., Nov. 15, 2017 /PRNewswire/ -- Promius Pharma LLC announced today that ZEMBRACE ® SymTouch ® (sumatriptan injection) 3 mg, an acute migraine headache treatment on the market since ...

Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...

Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...

Sumatriptan 5mg, 20mg; per spray. The vascular 5-HT 1 receptor subtype to which sumatriptan binds selectively, and through which it presumably exerts its antimigrainous effect, is present on cranial ...

MUMBAI, Feb 17 (Reuters) - Drug firm Wockhardt Ltd on Tuesday said it will be launching Sumatriptan injections in the U.S. following following final approval from the U.S. Food & Drug Administration.

Par Pharmaceutical Companies, Inc. said today it will pay Spectrum Pharmaceuticals, Inc., $20 million for more profits from a collaboration to sell a copycat migraine drug.Par Pharmaceutical Companies ...

OTTAWA, ONTARIO -- (Marketwired) -- 11/01/13 -- The issue: GlaxoSmithKline Inc., in consultation with Health Canada, is voluntarily recalling two lots of "IMITREX Injection", a migraine medication ...

Imitrex is available as a generic drug. The maximum single recommended adult dose of Imitrex Injection for the acute treatment of migraine or cluster headache is 6 mg injected subcutaneously. For the ...

Strategic Acquisition Helps Build Tonix’s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® ...

Nov 13 (Reuters) - Drugmaker Spectrum Pharmaceuticals Inc. on Monday said it settled a patent suit with GlaxoSmithKline relating to the UK-based company's migraine injection, Imitrex. Under the terms, ...

Chatham-based Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiary Tonix Medicines Inc. announced June 26 that they entered into an agreement to acquire two fast-acting migraine ...